Immuneering Co. (NASDAQ:IMRX) Shares Bought by Southport Management L.L.C.

Southport Management L.L.C. boosted its stake in shares of Immuneering Co. (NASDAQ:IMRX) by 4.9% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 215,000 shares of the company’s stock after acquiring an additional 10,000 shares during the period. Immuneering comprises about 1.7% of Southport Management L.L.C.’s holdings, making the stock its 24th biggest holding. Southport Management L.L.C.’s holdings in Immuneering were worth $473,000 as of its most recent filing with the SEC.

Other large investors also recently added to or reduced their stakes in the company. Marshall Wace LLP acquired a new position in Immuneering during the fourth quarter worth $47,000. HighTower Advisors LLC raised its position in shares of Immuneering by 33.7% in the fourth quarter. HighTower Advisors LLC now owns 71,360 shares of the company’s stock valued at $157,000 after buying an additional 18,000 shares during the last quarter. Rockefeller Capital Management L.P. acquired a new stake in shares of Immuneering in the fourth quarter valued at about $390,000. Bridgeway Capital Management LLC raised its position in shares of Immuneering by 77.4% in the fourth quarter. Bridgeway Capital Management LLC now owns 51,349 shares of the company’s stock valued at $113,000 after buying an additional 22,400 shares during the last quarter. Finally, First Manhattan CO. LLC. acquired a new stake in shares of Immuneering in the fourth quarter valued at about $71,000. 67.65% of the stock is currently owned by institutional investors and hedge funds.

Immuneering Trading Up 2.0%

Shares of IMRX opened at $1.29 on Friday. Immuneering Co. has a 12-month low of $1.00 and a 12-month high of $3.83. The firm has a 50-day moving average price of $1.41 and a 200 day moving average price of $1.76. The firm has a market capitalization of $46.24 million, a P/E ratio of -0.65 and a beta of -0.22.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings data on Monday, May 5th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.01). Equities research analysts predict that Immuneering Co. will post -1.86 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on IMRX shares. Oppenheimer reduced their target price on shares of Immuneering from $25.00 to $21.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Chardan Capital reissued a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a report on Tuesday, May 6th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $12.00 price objective on shares of Immuneering in a report on Thursday, April 10th.

Immuneering Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.